Foundations Investment Advisors LLC Increases Stake in Becton, Dickinson and Company (NYSE:BDX)

Foundations Investment Advisors LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 11.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,118 shares of the medical instruments supplier’s stock after buying an additional 119 shares during the period. Foundations Investment Advisors LLC’s holdings in Becton, Dickinson and were worth $275,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Icapital Wealth LLC purchased a new stake in shares of Becton, Dickinson and during the first quarter valued at approximately $31,000. Disciplined Investments LLC bought a new stake in shares of Becton, Dickinson and during the 1st quarter valued at $32,000. Rosenberg Matthew Hamilton grew its stake in Becton, Dickinson and by 61.5% during the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 48 shares in the last quarter. Core Alternative Capital grew its stake in Becton, Dickinson and by 688.2% during the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 117 shares in the last quarter. Finally, McIlrath & Eck LLC grew its stake in Becton, Dickinson and by 44.9% during the first quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 86.74% of the company’s stock.

Insider Activity at Becton, Dickinson and

In related news, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the completion of the sale, the executive vice president now owns 3,331 shares in the company, valued at approximately $882,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP David Hickey sold 475 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.00, for a total value of $125,875.00. Following the completion of the sale, the executive vice president now owns 3,331 shares in the company, valued at approximately $882,715. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Samrat S. Khichi sold 9,185 shares of the business’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the sale, the executive vice president now owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The disclosure for this sale can be found here. Insiders sold 19,160 shares of company stock worth $5,036,751 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Becton, Dickinson and Price Performance

Becton, Dickinson and stock opened at $254.32 on Monday. The firm has a 50-day moving average price of $251.96 and a 200-day moving average price of $254.68. The firm has a market capitalization of $72.53 billion, a PE ratio of 43.85, a price-to-earnings-growth ratio of 3.33 and a beta of 0.57. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. Becton, Dickinson and Company has a 12-month low of $231.46 and a 12-month high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The company had revenue of $4.64 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter last year, the business posted $2.74 EPS. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 11.31 EPS for the current year.

Becton, Dickinson and Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be issued a dividend of $0.87 per share. The ex-dividend date is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a yield of 1.37%. Becton, Dickinson and’s payout ratio is 60.00%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and cut their target price for the company from $265.00 to $235.00 in a research note on Monday, July 11th. Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective for the company in a research note on Friday, June 24th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday, September 10th. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research note on Monday, July 18th. Finally, The Goldman Sachs Group lifted their price objective on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $277.63.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.